Αρχική World News Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated...

Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively Treated Solid Malignancies

Results from an extensive, longitudinal follow-up of the Vax-On study of mRNA-BNT162b2 immunogenicity in patients with actively treated solid malignancies suggest that proximity to cancer treatment does not affect seroconversion response, which remains adequate even 5 months after the second COVID-19 vaccine dose. In contrast to healthy adults given full mRNA-vaccine schedule, antibody titre decreased markedly over time. Multivariate analysis ruled out the predictive value of a specific type of cancer treatment, but suggested a potential detrimental effect of corticosteroid therapy, male sex, and ECOG performance status (PS) 2 on humoral response.

These findings, along with the deployment of reliable assays for cellular immunity, may provide additional evidence in favour of the third dose of vaccine for actively treated patients with cancer, according to Dr Fabrizio Nelli of the Department of Oncology and Haematology, Medical Oncology Unit, Central Hospital of Belcolle in Viterbo, Italy and colleagues who published updated study findings on 9 December 2021 in the Annals of Oncology.

The authors wrote that their preliminary findings  confirmed a favourable safety profile and suggested that proximity to treatment hampers immune response to the first vaccine dose (timepoint-2). The second dose induced an exponential rise in anti-Spike protein IgG titre and seroconversion rates up to >90%, abrogating the disparity between the cohorts (timepoint-3). Antibody response assessment scheduled 6 months after the first dose served as a timepoint-4.

Patients on active treatment within 28 days of timepoint-4 represented the exposed cohort compared with the control cohort of those who had discontinued by at least 28 days. The present analysis involved 311 patients, including 203 in the exposed cohort, all of whom remained on active treatment from timepoint-3, and 108 in the control cohort.

The median IgG titre in control cohort versus exposed cohort, median log IgG titre, and seroconversion rates did not differ at timepoint-4. Compared with timepoint-3, paired assessment at timepoint-4 revealed a significant 4- to 6-fold decrease in median IgG titre within the same cohort (p < 0.001), with no difference for seroconversion rates.

Univariate comparison with the control cohort at timepoint-4 showed a significantly higher IgG titre for targeted therapy subgroup (p = 0.039), with a lower estimate for chemotherapy and biological agent subgroup (p = 0.035).

Multivariate analysis was performed by fitting a generalised linear model on log IgG titre and seroconversion response as a function of covariates significantly associated with immunogenicity after previous evaluation. Antibody response did not differ according to antineoplastic treatment subgroup. Male sex (p = 0.002) and ECOG PS2 (p = 0.02) were both significantly associated with lower log IgG titre, but only initial corticosteroid therapy was also related to lack of seroconversion (p = 0.005).

Only one case of mild COVID-19 was documented in the entire patient group after the second vaccine dose.

The authors concluded that their findings may provide additional evidence in favour of the third vaccine dose for actively treated patients with cancer.


Nelli F, Fabbri A, Onorato A, et al. Six-months immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: Updated results of the Vax-On study. Annals of Oncology; Published online 9 December 2021. DOI: https://doi.org/10.1016/j.annonc.2021.12.001



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...